Nektar Therapeutics buy Canaccord Genuity Group Inc.
Start price
22.07.26
/
50%
€0.58
Target price
22.07.27
€134.14
Performance (%)
-
Price
-
-
Summary
This prediction has just been started. It does not have a price yet.. This prediction currently runs until 22.07.27. The prediction end date can be changed by Canaccord_Genuity_Gr at any time.Nektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
AI-generated
Performance without dividends (%)
| Name | 1w |
|---|---|
| Nektar Therapeutics | - |
| iShares Core DAX® | 0.855% |
| iShares Nasdaq 100 | -0.989% |
| iShares Nikkei 225® | -1.781% |
| iShares S&P 500 | 0.057% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NKTR) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $153.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat